Decoglurant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Decoglurant
Decoglurant.svg
Systematic (IUPAC) name
5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]pyridin-2-amine
Clinical data
Identifiers
911115-16-7
None
PubChem CID 71533696
Chemical data
Formula C21H11F6N5
447.336 g/mol

Decoglurant (INN) (code name RG1578, RO4995819) is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder.[1][2] Decoglurant progressed as far as phase II clinical trials[1][2] but was ultimately discontinued from further development due to disappointing efficacy results.[3][4]

See also[edit]

References[edit]

  1. ^ a b "Roche - Pipeline". 2014. Retrieved 2014-08-01. 
  2. ^ a b "Roche Group Development Pipeline" (PDF). 2014. Retrieved 2014-08-01. 
  3. ^ "Roche - Pipeline" (PDF). 2015. Retrieved 2015-05-14. 
  4. ^ Janna Lawrence (March 2015). "The Secret Life of ketamine". The Pharmaceutical Journal 294 (7854/5). 

External links[edit]